JAC Advance Access originally published online on February 25, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2003) 51, 963-970
© 2003 The British Society for Antimicrobial Chemotherapy
Prior antimicrobial drug exposure: a risk factor for trimethoprim–sulfamethoxazole-resistant urinary tract infections
1 Center for Health Equity Research and Promotion, Philadelphia Veterans Affairs Medical Center; 2 Departments of Medicine and Biostatistics and Epidemiology, the Center for Clinical Epidemiology and Biostatistics, the Center for Education and Research on Therapeutics, and the Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA, USA
Received 11 October 2001; returned 21 May 2002; revised 21 October 2002; accepted 27 December 2002
Objectives: Antimicrobial drug use is believed to be an important risk factor for the emerging problem of antimicrobial drug resistance, yet strong evidence for the causal relationship in community settings has been limited. Detailed analysis of this risk factor at the level of the individual patient has been hampered by limited availability of drug exposure data among patients with outpatient infections. We used a novel data system to identify patterns of individual antimicrobial drug exposures associated with trimethoprim–sulfamethoxazole-resistant urinary tract infections (UTIs).
Materials and methods: This was a retrospective case–control study. Subjects were veterans with Gram-negative UTIs seen at the Philadelphia VA Medical Center from 1 July 1996 to 31 December 1999. Subjects were linked to a national VA outpatient pharmacy database. Cases and controls were identified based on the results of trimethoprim–sulfamethoxazole susceptibility testing.
Results: Three hundred and ninety-three veterans with UTIs could be linked to electronic pharmacy records. The overall rate of trimethoprim–sulfamethoxazole drug resistance was 13%, without significant annual variation. Antimicrobial drug exposure within 6 months was strongly associated with the probability of a trimethoprim–sulfamethoxazole-resistant infection (OR = 4.1, 95% CI 2.2–7.5). This association extended to exposure to other antimicrobial drugs in addition to trimethoprim–sulfamethoxazole and the overall association displayed a dose–response relationship in terms of the number of prior drug exposures.
Conclusions: Prior antimicrobial drug exposure is a strong risk factor for infection with trimethoprim–sulfamethoxazole-resistant Gram-negative bacteria among patients with UTIs.
* Corresponding author. Tel: +1-215-898-1484; Fax: +1-215-573-5325; E-mail: jmetlay{at}cceb.med.upenn.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Colgan, J. R. Johnson, M. Kuskowski, and K. Gupta Risk Factors for Trimethoprim-Sulfamethoxazole Resistance in Patients with Acute Uncomplicated Cystitis Antimicrob. Agents Chemother., March 1, 2008; 52(3): 846 - 851. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hillier, Z. Roberts, F. Dunstan, C. Butler, A. Howard, and S. Palmer Prior antibiotics and risk of antibiotic-resistant community-acquired urinary tract infection: a case-control study J. Antimicrob. Chemother., July 1, 2007; 60(1): 92 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Hay, M. Thomas, A. Montgomery, M. Wetherell, A. Lovering, C. McNulty, D. Lewis, B. Carron, E. Henderson, and A. MacGowan The relationship between primary care antibiotic prescribing and bacterial resistance in adults in the community: a controlled observational study using individual patient data J. Antimicrob. Chemother., July 1, 2005; 56(1): 146 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Magee, M. L. Heginbothom, and B. W. Mason Finding a strategy: the case for co-operative research on resistance epidemiology J. Antimicrob. Chemother., May 1, 2005; 55(5): 628 - 633. [Abstract] [Full Text] [PDF]
|
|